Emerging Roles for UDP-glucuronosyltransferases in Drug Resistance and Cancer Progression

Overview

Journal Br J Cancer

Specialty Oncology

Date 2020 Feb 13

PMID 32047295

Citations 50

Authors

Eric P Allain

Michele Rouleau

Eric Levesque

Chantal Guillemette

Affiliations

Soon will be listed here.

Abstract

The best-known role of UDP-glucuronosyltransferase enzymes (UGTs) in cancer is the metabolic inactivation of drug therapies. By conjugating glucuronic acid to lipophilic drugs, UGTs impair the biological activity and enhance the water solubility of these agents, driving their elimination. Multiple clinical observations support an expanding role for UGTs as modulators of the drug response and in mediating drug resistance in numerous cancer types. However, accumulating evidence also suggests an influence of the UGT pathway on cancer progression. Dysregulation of the expression and activity of UGTs has been associated with the progression of several cancers, arguing for UGTs as possible mediators of oncogenic pathways and/or disease accelerators in a drug-naive context. The consequences of altered UGT activity on tumour biology are incompletely understood. They might be associated with perturbed levels of bioactive endogenous metabolites such as steroids and bioactive lipids that are inactivated by UGTs or through non-enzymatic mechanisms, thereby eliciting oncogenic signalling cascades. This review highlights the evidence supporting dual roles for the UGT pathway, affecting cancer progression and drug resistance. Pharmacogenomic testing of UGT profiles in patients and the development of therapeutic options that impair UGT actions could provide useful prognostic and predictive biomarkers and enhance the efficacy of anti-cancer drugs.

Citing Articles

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.

Li P, Huang M, Li M, Li G, Ma Y, Zhao Y J Exp Clin Cancer Res. 2025; 44(1):72.

PMID: 40001264 PMC: 11863571. DOI: 10.1186/s13046-025-03332-8.

Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins.

Shi Z, Han S Heliyon. 2025; 11(1):e41629.

PMID: 39866414 PMC: 11761934. DOI: 10.1016/j.heliyon.2025.e41629.

Does Bisphenol A (BPA) Exposure Cause Human Diseases?.

Stein T Biomedicines. 2025; 12(12.

PMID: 39767585 PMC: 11727305. DOI: 10.3390/biomedicines12122678.

Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control.

Huang X, Chen W, Wang Y, Shytikov D, Wang Y, Zhu W Front Med. 2025; 19(1):23-52.

PMID: 39745621 DOI: 10.1007/s11684-024-1107-1.

A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.

Leon-Letelier R, Chen Y, Ballaro R, Irajizad E, Do K, Maitra A J Cancer Immunol (Wilmington). 2024; 6(4):148-153.

PMID: 39713022 PMC: 11661815. DOI: 10.33696/cancerimmunol.6.095.

References

Meech R, Hu D, McKinnon R, Mubarokah S, Haines A, Nair P . The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms. Physiol Rev. 2019; 99(2):1153-1222. DOI: 10.1152/physrev.00058.2017. View

Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A . Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. Pharmacogenomics J. 2017; 18(2):251-261. DOI: 10.1038/tpj.2017.5. View

Rowland A, Miners J, Mackenzie P . The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013; 45(6):1121-32. DOI: 10.1016/j.biocel.2013.02.019. View

Hu D, Mackenzie P, McKinnon R, Meech R . Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. Drug Metab Rev. 2016; 48(1):47-69. DOI: 10.3109/03602532.2015.1131292. View

Guillemette C . Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003; 3(3):136-58. DOI: 10.1038/sj.tpj.6500171. View

Nagar S, Remmel R . Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene. 2006; 25(11):1659-72. DOI: 10.1038/sj.onc.1209375. View

Mackenzie P, Rogers A, Treloar J, Jorgensen B, Miners J, Meech R . Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem. 2008; 283(52):36205-10. PMC: 2662294. DOI: 10.1074/jbc.M807961200. View

Gessner T, Vaughan L, Beehler B, Bartels C, Baker R . Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res. 1990; 50(13):3921-7. View

Franklin T, Jacobs V, Jones G, Ple P, Bruneau P . Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res. 1996; 56(5):984-7. View

10.

Takahashi T, Fujiwara Y, Yamakido M, Katoh O, Watanabe H, Mackenzie P . The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res. 1998; 88(12):1211-7. PMC: 5921346. DOI: 10.1111/j.1349-7006.1997.tb00351.x. View

11.

Romero-Lorca A, Novillo A, Gaibar M, Bandres F, Fernandez-Santander A . Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. PLoS One. 2015; 10(7):e0132269. PMC: 4503404. DOI: 10.1371/journal.pone.0132269. View

12.

Sutiman N, Lim J, Muerdter T, Singh O, Cheung Y, Ng R . Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. Clin Pharmacokinet. 2016; 55(10):1239-1250. DOI: 10.1007/s40262-016-0402-7. View

13.

Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y . Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One. 2014; 9(5):e96664. PMC: 4010532. DOI: 10.1371/journal.pone.0096664. View

14.

Innocenti F, Schilsky R, Ramirez J, Janisch L, Undevia S, House L . Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014; 32(22):2328-34. PMC: 4105486. DOI: 10.1200/JCO.2014.55.2307. View

15.

Cummings J, Boyd G, Ethell B, Macpherson J, Burchell B, Smyth J . Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol. 2002; 63(4):607-13. DOI: 10.1016/s0006-2952(01)00812-7. View

16.

Cummings J, Ethell B, Jardine L, Boyd G, Macpherson J, Burchell B . Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003; 63(23):8443-50. View

17.

Raynal C, Pascussi J, Leguelinel G, Breuker C, Kantar J, Lallemant B . Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010; 9:46. PMC: 2838814. DOI: 10.1186/1476-4598-9-46. View

18.

Campbell J, Stephenson M, Bateman E, Peters M, Keefe D, Bowen J . Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J. 2016; 17(1):21-28. DOI: 10.1038/tpj.2016.58. View

19.

Miyata Y, Nakamoto H, Neckers L . The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des. 2012; 19(3):347-65. PMC: 7553218. DOI: 10.2174/138161213804143725. View

20.

Neckers L, Trepel J . Stressing the development of small molecules targeting HSP90. Clin Cancer Res. 2013; 20(2):275-7. DOI: 10.1158/1078-0432.CCR-13-2571. View